<SEC-DOCUMENT>0001395064-26-000100.txt : 20260325
<SEC-HEADER>0001395064-26-000100.hdr.sgml : 20260325
<ACCEPTANCE-DATETIME>20260325060359
ACCESSION NUMBER:		0001395064-26-000100
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260325
FILED AS OF DATE:		20260325
DATE AS OF CHANGE:		20260325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TAKEDA PHARMACEUTICAL CO LTD
		CENTRAL INDEX KEY:			0001395064
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38757
		FILM NUMBER:		26788245

	BUSINESS ADDRESS:	
		STREET 1:		1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-8668
		BUSINESS PHONE:		81332782111

	MAIL ADDRESS:	
		STREET 1:		1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-8668
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k_032526.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic867af0d6c554b16a1774f5ec11ab562_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:139%">FORM&#160;6-K</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:139%">U.S. SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">Washington, D.C. 20549</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">Report of Foreign Private Issuer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">Pursuant to Rule&#160;13a-16&#160;or&#160;15d-16&#160;of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">the Securities Exchange Act of 1934</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">For the month of March 2026</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Commission File Number&#58;&#160;001-38757</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:22pt;font-weight:700;line-height:139%">TAKEDA PHARMACEUTICAL COMPANY LIMITED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">(Translation of registrant&#8217;s name into English)</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">1-1, Nihonbashi-Honcho 2-Chome</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Chuo-ku, Tokyo&#160;103-8668</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Japan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:139%">(Address of principal executive offices)</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:139%">Form&#160;20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</font></div><div style="margin-top:12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:139%">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(1)&#58;&#160;&#160;&#9744;</font></div><div style="margin-top:12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:139%">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(7)&#58;&#160;&#160;&#9744;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><div id="ic867af0d6c554b16a1774f5ec11ab562_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">Information furnished on this form&#58;</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">EXHIBIT</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.352%"><tr><td style="width:1.0%"></td><td style="width:8.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.456%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">Exhibit</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">Number</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:3.6pt;padding-left:36pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ic867af0d6c554b16a1774f5ec11ab562_84" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook</a></font></div></td></tr></table></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><div id="ic867af0d6c554b16a1774f5ec11ab562_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURES</font></div><div style="margin-top:12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:31.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.932%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TAKEDA PHARMACEUTICAL COMPANY LIMITED</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 25, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Norimasa Takeda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">Norimasa Takeda</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">Chief Accounting Officer and Corporate Controller</font></div></td></tr></table></div><div style="margin-top:7pt;text-indent:24pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><div id="ic867af0d6c554b16a1774f5ec11ab562_84"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:400;line-height:125%">News Release</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3.6pt;padding-left:10.5pt;padding-right:10.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.00pt">OSAKA, Japan and CAMBRIDGE, Massachusetts, March 25, 2026</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt"> &#8211; Takeda  (TSE&#58;4502&#47;NYSE&#58;TAK) announced today its Board of Directors approved the next steps in the Company's transformation to strengthen competitiveness, enhance its long-term growth profile and accelerate launch execution in the years ahead. The transformation, aligned with the previously announced organizational structure, is expected to deliver annualized gross savings of more than JPY 200 billion by FY2028, positioning the company for its next era. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">Increased efficiencies from the transformation will be achieved through streamlining of corporate functions, bringing leadership and teams closer to patients and customers and process simplification made possible by advanced technologies. These efficiencies will largely offset investments needed to prepare for multiple launches, including oveporexton, rusfertide and zasocitinib, progress the late-stage pipeline and support strategic technology investments.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">&#8220;Today, Takeda is setting the stage to make a greater impact on the lives of patients as we prepare to launch multiple new medicines and continue to deliver on the promise of our pipeline,&#8221; said Julie Kim, CEO-Elect, Takeda. &#8220;The deliberate steps we are taking will strengthen our ability to execute with speed while strategically prioritizing resources and positioning ourselves for long-term growth and success in the next era.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">As a result of these initiatives, Takeda currently estimates it will incur restructuring expenses of approximately JPY 150 billion in FY2026, with lower restructuring expenses also anticipated in FY2027 and FY2028. The FY2026 restructuring expenses will be reflected in the Company&#8217;s consolidated financial forecast for FY2026 to be announced in the FY2025 full-year earnings announcement. Details and timing of specific initiatives will be determined in due course. There is no significant impact on the full-year consolidated financial forecast for FY2025 from these initiatives.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:125%">About Takeda</font></div><div style="margin-bottom:8pt;padding-right:-0.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:15.00pt">Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business&#160;areas, including gastrointestinal and&#160;inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and&#160;vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&#38;D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.00pt">Contacts</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.00pt">Investor Relations</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">Christopher O&#8217;Reilly</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:14.00pt"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">Christopher.oreilly&#64;takeda.com</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">+81 (0) 90-6481-3412</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.00pt">Media Relations</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:14.00pt">Media_Relations&#64;takeda.com</font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.00pt">Important Notice</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">For the purposes of this notice, &#8220;press release&#8221; means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, &#8220;Takeda&#8221; is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.519%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.00pt">Forward-Looking Statements</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">This press release</font><font style="color:#34373f;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:14.00pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda&#8217;s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as &#8220;targets&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;hopes&#8221;, &#8220;continues&#8221;, &#8220;expects&#8221;, &#8220;aims&#8221;, &#8220;intends&#8221;, &#8220;ensures&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;anticipates&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;forecasts&#8221;, &#8220;outlook&#8221; or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements&#58; the economic circumstances surrounding Takeda&#8217;s global business, including general economic conditions in Japan and the United States and with respect to international trade relations&#59; competitive pressures and developments&#59; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules&#59; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof&#59; uncertainty of commercial success for new and existing products&#59; manufacturing difficulties or delays&#59; fluctuations in interest and currency exchange rates&#59; claims or concerns regarding the safety or efficacy of marketed products or product candidates&#59; the impact of health crises, like the novel coronavirus pandemic&#59; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals&#59; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits&#59; and other factors identified in Takeda&#8217;s most recent Annual Report on Form 20-F and Takeda&#8217;s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda&#8217;s website at&#58; https&#58;&#47;&#47;www.takeda.com&#47;investors&#47;sec-filings-and-security-reports&#47; or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda&#8217;s future results.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:14.00pt">###</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.519%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
